Inventor · disambiguated record
Steven P. Langston
Also filed as: LANGSTON STEVEN · LANGSTON STEVEN P · LANGSTON STEVEN PAUL
25 granted patents·14 pending applications·156 citations·filing 2006–2024
96Inventor score
Files withMILLENNIUM PHARM INC27TAKEDA PHARMACEUTICALS CO4LANGSTON STEVEN P3ARMITAGE IAN G1ARMITAGE Ian1
Top patents by PatentIndex Score
39 records- 0197US8008307B2Heteroaryl compounds useful as inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2007·Granted Aug 30, 2011·25 cites·17 claims
- 0295US8481550B2Heteroaryl compounds useful as inhibitors of E1 activating enzymesCLAIBORNE CHRISTOPHER F·Filed 2011·Granted Jul 9, 2013·19 cites·14 claims
- 0394US9150525B2Heteroaryl compounds useful as inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2014·Granted Oct 6, 2015·10 cites·19 claims
- 0493US8901136B2Heteroaryl compounds useful as inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2013·Granted Dec 2, 2014·12 cites·9 claims
- 0592US8207177B2Inhibitors of E1 activating enzymesLANGSTON STEVEN P·Filed 2007·Granted Jun 26, 2012·26 cites·9 claims
- 0692US7951810B2Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2006·Granted May 31, 2011·16 cites·19 claims
- 0788US9962386B2Heteroaryl compounds useful as inhibitors of SUMO activating enzymeMILLENNIUM PHARM INC·Filed 2017·Granted May 8, 2018·6 cites·39 claims
- 0888US9458108B2Heteroaryl compounds useful as inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2015·Granted Oct 4, 2016·3 cites·18 claims
- 0987US9683003B2Heteroaryl compounds useful as inhibitors of SUMO activating enzymeMILLENNIUM PHARM INC·Filed 2015·Granted Jun 20, 2017·7 cites·55 claims
- 1087US9290500B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2013·Granted Mar 22, 2016·10 cites·41 claims
- 1186US10335410B2Heteroaryl compounds useful as inhibitors of sumo activating enzymeMILLENNIUM PHARM INC·Filed 2018·Granted Jul 2, 2019·4 cites·14 claims
- 1285US10780090B2Heteroaryl compounds useful as inhibitors of SUMO activating enzymeMILLENNIUM PHARM INC·Filed 2019·Granted Sep 22, 2020·1 cites·16 claims
- 1380US2023293522A1Heteroaryl compounds useful as inhibitors of sumo activating enzymeTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 1479US11542293B2Sting modulator compounds, and methods of making and usingTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Jan 3, 2023·1 cites·23 claims
- 1578US10745404B2Process for the synthesis of E1 activating enzyme inhibitorsMILLENNIUM PHARM INC·Filed 2017·Granted Aug 18, 2020·1 cites·7 claims
- 1677US9695154B2Heteroaryl inhibitors of sumo activating enzymeMILLENNIUM PHARM INC·Filed 2014·Granted Jul 4, 2017·4 cites·34 claims
- 1776US2025262298A1Sting modulator compounds with sulfamate linkages, and methods of making and usingCIAVARRI JEFFREY·Filed 2024·Application pending·0 cites
- 1875US9802938B2Sulfamoylating reagentsMILLENNIUM PHARM INC·Filed 2014·Granted Oct 31, 2017·2 cites·18 claims
- 1974US8933225B2Process for the synthesis of E1 activating enzyme inhibitorsARMITAGE Ian·Filed 2008·Granted Jan 13, 2015·2 cites·14 claims
- 2072US9663525B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2016·Granted May 30, 2017·1 cites·12 claims
- 2172US2022331316A1Heteroaryl compounds useful as inhibitors of sumo activating enzymeMILLENNIUM PHARM INC·Filed 2020·Application pending·0 cites
- 2270US12054512B2Sting modulator compounds, and methods of making and usingTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Aug 6, 2024·0 cites·23 claims
- 2370US9187482B2Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamateARMITAGE IAN G·Filed 2010·Granted Nov 17, 2015·3 cites·29 claims
- 2470US2021070798A1Inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2020·Application pending·0 cites
- 2569US9139589B2Heteroaryls and uses thereofHIROSE MASAAKI·Filed 2010·Granted Sep 22, 2015·2 cites·28 claims
- 2668US10016427B2Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamateMILLENNIUM PHARM INC·Filed 2015·Granted Jul 10, 2018·1 cites·23 claims
- 2767US9718788B2Heteroaryl compounds useful as inhibitors of E1 activating enzymesMILLENNIUM PHARM INC·Filed 2016·Granted Aug 1, 2017·0 cites·1 claims
- 2866US2017073367A9Substituted pyrrolo[2,3-d]pyrimidinesMILLENNIUM PHARM INC·Filed 2014·Application pending·0 cites
- 2966US2019255052A1Inhibitors of E1 Activating EnzymesMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 3062US2014256668A9Substituted pyrrolo]2,3-d]pyrimidinesMILLENNIUM PHARM INC·Filed 2013·Application pending·0 cites
- 3162US2013289037A1Inhibitors of e1 activting enzymesMILLENNIUM PHARM INC·Filed 2013·Application pending·0 cites
- 3262US2018086785A1Substituted pyrrolo[2,3-d]pyrimidinesMILLENNIUM PHARM INC·Filed 2017·Application pending·0 cites
- 3361US10202389B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2017·Granted Feb 12, 2019·0 cites·7 claims
- 3461US9796725B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2017·Granted Oct 24, 2017·0 cites·15 claims
- 3561US2021015915A1Sting modulator compounds with sulfamate linkages, and methods of making and usingTAKEDA PHARMACEUTICALS CO·Filed 2019·Application pending·0 cites
- 3660US2017136024A1Inhibitors of e1 activating enzymesMILLENNIUM PHARM INC·Filed 2016·Application pending·0 cites
- 3757US2011136834A1Inhibitors of e1 activating enzymesMILLENNIUM PHARM INC·Filed 2011·Application pending·0 cites
- 3857US2012258927A1Inhibitors of e1 activating enzymesLANGSTON STEVEN P·Filed 2012·Application pending·0 cites
- 3957US2013165457A9Inhibitors of e1 activating enzymesLANGSTON STEVEN P·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven P. Langston files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →